In this issue:
NCCN prostate cancer update (version 2.2026/3.2026)
Changes to the EAU prostate cancer guideline
PCFA submission to NHMRC: 2025 guidelines for early detection of PC
Pluvicto Australian approval documentation published
Section 19a approval for illuccix (ga-68 gozetotide) supply pathway
FDA approval of Rubraca (rucaparib) for BRCA-mutated mCRPC
Akeega (niraparib + abiraterone) FDA expanded to BRCA2m mCSPC
“World-first” Australian trial press release: New combination for advanced PC
Update on current prostate cancer trials
Heading to ASCO 2026?
PBS general copayment cap change, effective 1 January 2026
Conferences, Workshops, CPD
Research Review Publications
Please login below to download this issue (PDF)